Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Base Year
Historical Year
Forecast Year
The global antifungal drugs market value was USD 15.35 billion in 2023, driven by the increasing prevalence of fungal infections across the globe. The global antifungal drugs market share is anticipated to grow at a CAGR of 3.7% during the forecast period of 2024-2032 to achieve a value of USD 21.28 billion by 2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Based on drug class, the azoles segment accounts for a significant share in the market and is anticipated to witness a considerable growth in the forecast period. Azoles are used to treat a wide range of conditions, including yeast infection, tinea versicolor, and athlete's foot, and are available in different formulations, such as capsules, lotions, and sterile IV solutions, among others. These drugs offer improved absorption and distribution properties with fewer side effects and less serious drug interactions.
These factors have been contributing to the growth of the segment. Over the forecast period, the rising demand for azoles in combination with other antifungal agents to treat systematic and superficial fungal infections is likely to be a major factor driving the market. In addition to this, the growing cases of candidemia, blastomycosis, systematic candidiasis, and ocular fungal infections, among others are likely to aid the segment growth in the coming years.
North America accounts for a significant market share in the antifungal drugs industry due to the improved healthcare infrastructure, rise in echinocandin resistance, and the growing cases of fungal infections in the region. The growing pharmaceutical industry and the presence of the leading companies in the region are supporting the market growth in North America. Moreover, the increasing commercialisation of drugs is expected to further contribute to the antifungal drugs industry growth in the region.
Antifungal drugs can be defined as a type of drug that helps eliminate fungal infection from the body with minimum toxic side effects. Antifungal drugs basically act against fungal pathogens and are used in the treatment of fungal infections.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Based on drug class, the market is segmented into:
On the basis of indication, the industry is divided into:
The regional markets for the product include North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The global market for antifungal drugs is driven by the growing prevalence of fungal infections across the globe. The increasing consumption of unhealthy food, which might compromise the immune system, is likely to increase the risk of fungal infections, which, in turn, is expected to propel the demand for antifungal drugs. Furthermore, the rising geriatric population, which is more susceptible to fungal infections such as ringworm, candidiasis, and systematic mycosis, among others, is significantly contributing to the market growth.
Over the forecast period, the growing investments by the leading pharmaceutical companies to develop novel and more effective drugs for fungal diseases are anticipated to augment the market growth in the forecast period.
The report gives a detailed analysis of the following key players in the global antifungal drugs market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:
The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.
REPORT FEATURES | DETAILS |
Base Year | 2023 |
Historical Period | 2017-2023 |
Forecast Period | 2024-2032 |
Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
Breakup by Drug Class |
|
Breakup by Indication |
|
Breakup by Dosage Form |
|
Breakup by Distribution Channel |
|
Breakup by Region |
|
Market Dynamics |
|
Supplier Landscape |
|
Companies Covered |
|
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
The antifungal drugs market was valued at USD 15.35 billion in 2023.
The market is expected to grow at a CAGR of 3.7% from 2024 to 2032 to reach a value of USD 21.28 billion by 2032.
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
The major drivers of the market include rising population of the geriatrics, commercialisation of antifungal drugs, growing investments by the leading pharmaceutical companies, improved healthcare infrastructure, rise in echinocandin resistance, and growing pharmaceutical industry.
The growing prevalence of fungal infections and increasing consumption of unhealthy food are the key trends guiding the growth of the industry.
Azoles, echinocandins, polyenes, and allylamines, among others are the major drug classes of the market. Azoles is further divided into voriconazole, posaconazole, and isavuconazole (CRESEMBA), among others whereas echinocandins is sub-divided into caspofungin and micafungin (mycamine/ funguard), among others. Among these, polyenes are segmented into amphotericin (ambisome), among others while allylamines is segmented into terbinafine, among others.What are the different indications based on which the market is segmented?Dermatophytosis, aspergillosis and candidiasis, among others are the different indications based on which the market is segmented. Candidiasis is further segmented into invasive candidiasis, vulvovaginal candidiasis (VVC), and mouth/throat/esophageal candidiasis, among others.
The major players in the industry are Abbott Laboratories, GlaxoSmithKline PLC, Novartis AG, and Pfizer Inc., among others.
Purchase Full Report
Datasheet
Single User License
One User
Five User License
Five Users
Corporate License
Unlimited Users
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61 448 06 17 27
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63 287899028, +63 967 048 3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84865399124